That's a great question. Of course, that's why we're here today.
We really need to look at a new governance system to properly monitor development. In the case of BioCanRx, it's the development of a product from discovery to the clinical trial. Right now, there's no way to have a new system, but non-profit organizations like ours, which are funded by the strategic science fund, are used to manage the immunotherapy development pathway.
Better governance between organizations is really something that should be considered for developments related to the various diseases patients are grappling with across Canada.
